中国中西医结合杂志2024，Vol.44Issue(7)：806-813,8.DOI:10.7661/j.cjim.20240418.077
龙柴降血方治疗原发性血小板增多症随机对照研究
Longchai Jiangxue Formula for the Treatment of Essential Thrombocythemia:A Randomized Controlled Study
摘要
Abstract
Objective To evaluate the efficacy,anticoagulant role,and effect on aspirin resistance(AR)of Longchai Jiangxue Formula(LCJX)in treating essential thrombocythemia(ET).Methods Seventy-two patients with ET met the inclusion criteria at the Department of Hematology,Xiyuan Hospital,China Academy of Chinese Medical Sciences,from October 2021 to December 2022,and were assigned to the control group and the observation group,with 36 cases in each group by using the method of randomized numerical table.The control group was given hydroxycarbamide≤1.0 g/d or pegylated interferon-α2a(PEG-INF α-2a)≤180 g/w or IFN-α-2b ≤ 9 million U/w,and aspirin ≤ 100 mg/d.The observation group added LCJX based on the control group treatment.Platelet counts,myeloproliferative neoplasm(MPN)-10 scores,disease progression and thrombosis or bleeding events were observed before and after treatment.Prothrombin time(PT),fibrinogen(FIB),D-Dimer(D-Di),activated partial thromboplastin time(APTT),platelet count(PLT),coagulation index(Cl),and maximal amplitude(MA)of thromboelastography(TEG)were used to assess the presence of hypercoagulable state in the patients as well as the effect of LCJX on coagulation function.Arachidonic acid(AA)-induced AA inhibition in TEG was applied to assess the occurrence of AR in patients with ET and the role of LCJX on AR.Results Among 72 patients,7 patients dropped off and 65 patients could be evaluated,32 in the observation group and 33 in the control group.Compared with the control group,the observation group showed a higher effective rate and lower PLT count and MPN-10 score(P＜0.05).No disease progression or thrombotic or bleeding events occurred in both groups during the treatment period.Of the two groups,29 patients(44.62％)were in a hypercoagulable state,14 cases in the control group and 15 cases in the observation group.Compared with the control group,the proportion of patients with hypercoagulable state was significantly lower in the observation group after treatment(P＜0.05).The incidence of AR in ET patients was 46.15％(30/65),16 patients in the control group and 14 in the observation group.Compared with the control group,the incidence of AA inhibition was significantly higher in the observation group(P＜0.05).No obvious adverse reactions occurred in the two groups.Conclusion LCJX can effectively reduce blood cell counts,improve symptoms,increase efficiency,and improve hypercoagulable state and AR in patients with ET.关键词
原发性血小板增多症/龙柴降血方/血小板计数/高凝状态/阿司匹林抵抗/中西医结合/随机对照试验Key words
essential thrombocythemia/Longchai Jiangxue Formula/platelet count/hypercoagulable state/aspirin resistance/integrative medicine/randomized controlled trial引用本文复制引用
孙妍,陈卓,胡晓梅,杨二鹏,李雨蒙,牛继聪,陈科,邹吉轩,王明镜,刘为易,吕妍..龙柴降血方治疗原发性血小板增多症随机对照研究[J].中国中西医结合杂志,2024,44(7):806-813,8.基金项目
国家自然科学基金面上项目(No.82174360) （No.82174360）
中国中医科学院科技创新工程重大攻关项目(No.CI2021A01702,No.CI2021A01708) （No.CI2021A01702,No.CI2021A01708）
中国中医科学院科技创新工程重点协同攻关项目(No.CI2023C027YL) （No.CI2023C027YL）
